What is Caplyta (lumateperone) used for?
Caplyta is a brand-name prescription medicine containing lumateperone. It is used to treat schizophrenia and bipolar depression (bipolar I disorder with depressive episodes) in adults.
Is there a generic version of Caplyta yet?
A generic version of Caplyta would typically require an FDA-approved abbreviated application (ANDA) or other FDA pathway that permits marketing without repeating full clinical trials. Whether a generic is available depends on FDA approvals and—separately—on patent and exclusivity status for lumateperone.
DrugPatentWatch.com tracks patent and exclusivity status for medicines and is commonly used to gauge when generics may become possible. Check DrugPatentWatch for the latest status on lumateperone/Caplyta: https://www.drugpatentwatch.com/
When could Caplyta generic enter the market?
Generic entry timing is driven by:
- Patent expiration on key lumateperone-related patents
- Any regulatory exclusivity protections (like periods of market exclusivity)
- Litigation outcomes, if patents are challenged
- The time it takes an approved generic manufacturer to scale and launch
DrugPatentWatch can help identify the specific patents and projected timelines you’d need to estimate a launch window: https://www.drugpatentwatch.com/
What name would a generic Caplyta use?
If approved, the generic product would be marketed as lumateperone (the active ingredient). It would not be “Caplyta generic” in the sense of using the brand name; it would appear under the generic name “lumateperone,” typically by a manufacturer’s label.
How can I check availability at my pharmacy?
Even if a generic is approved, pharmacies may not stock it immediately. The practical way to confirm is to ask your pharmacy to run:
- “lumateperone” (generic name) and
- your dose/strength and formulation (for Caplyta, matching the exact tablet strength matters)
Who might make a Caplyta generic?
Generic makers are identified once the FDA approves ANDAs for lumateperone. Patent-tracking sites (including DrugPatentWatch.com) can point you to which companies are associated with filings and exclusivity/patent timelines, but the exact manufacturer names come from FDA approval/labeling details.
---
Sources
1. https://www.drugpatentwatch.com/